Lebensqualit�t bei Patienten mit berufsbedingten Handekzemen

Coenraads, Pieter Jan; Bouma, J.; Diepgen, Thomas L.

doi:10.1007/s00105-003-0659-2

Cited by 22 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Questionnaires such as the SF-36 or DLQI list very few items on the visible lesions. Therefore, it seemed relevant for Coenraads et al [22 ]to propose a questionnaire which examined the impact of lesions on the patient’s occupational life (i.e. relationships with colleagues), since it is important to take this parameter into account.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Atopic Dermatitis: Impact on the Quality of Life of Patients and Their Partners

Miséry¹,

et al. 2007

View full text Add to dashboard Cite

Background: The impact of atopic dermatitis (AD) on the patient’s quality of life is relatively well known. However, the influence on the patient’s spouse has never been studied. Objective: To evaluate the impact of AD on the quality of life, sleeping and sexual life of patients and their partners. Methods: In this cross-sectional study, patients and their partners completed a number of questionnaires asking about their general health and their quality of life [Short Form 12, Epworth, Dermatology Life Quality Index (DLQI)] and completed an idiosyncratic measure asking about their sexual functioning. AD severity was clinician rated using Scoring atopic dermatitis (SCORAD). Results: A total of 266 patients were included. The mean DLQI score was 8.8. The physical and mental composite 12 scores were 50.7 and 39.5, respectively. These 3 scores were significantly related to SCORAD. A decrease in sexual desire due to AD was noted in 57.5% of patients. The quality of life of partners did not appear to be particularly impaired, but 36.5% reported that the appearance of eczema had an impact on their sex life. Conclusion: The influence of AD on sex life is significant both for the patients and their partners.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A German study [22] investigated the impact, in particular the occupational one, of the presence of lesions on the hands. Questionnaires such as the SF-36 or DLQI list very few items on the visible lesions.…”

Section: Discussionmentioning

confidence: 99%

Atopic Dermatitis: Impact on the Quality of Life of Patients and Their Partners

Miséry¹,

et al. 2007

View full text Add to dashboard Cite

show abstract

“…It presents a standardized, validated, well-accepted and simple tool. Due to its simplicity, it is used in clinical trials and even clinical routine 7 especially for psoriasis, 8 acne, 9 eczema, [10][11][12] as well as for keloid, 13 vitiligo and other skin dis-eases. [14][15][16] To the best of our knowledge, there is no data on the impact on QoL caused by adverse reactions due to injectable filler substances.…”

Section: Introductionmentioning

confidence: 99%

The impact of adverse reactions to injectable filler substances on quality of life: results from the Berlin Injectable Filler Safety (IFS) – study

Düker

Erdmann

Hartmann

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Despite the currently available therapies, the illness leads frequently to a chronic course [1,2]. It is well known that patient's quality of life is affected negatively by restricted function of the hands, severe psychological strain and also economical implications [3-5]. …”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective

Blank

Blank²,

Szucs

2010

BMC Dermatol

View full text Add to dashboard Cite

BackgroundThe impact on patients suffering from chronic hand eczema (CHE) is enormous, as no licensed systemic treatment option with proven efficacy for CHE is available. Alitretinoin is a novel agent which showed high clinical efficacy in patients with severe, refractory CHE. We assessed the cost-effectiveness of alitretinoin for CHE patient treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of disease in Switzerland.MethodsA long-term Markov cohort simulation model was used to estimate direct medical costs (€) and clinical effectiveness (quality adjusted life years, QALYs) of treating severe CHE patients with alitretinoin. Comparison was against the standard treatment of supportive care (optimised emollient therapy). Information on response rates were derived from a randomized controlled clinical trial. Costs were considered from the perspective of the Swiss health system. Swiss epidemiological data was derived from official Swiss Statistic institutions.ResultsAnnual costs of alitretinoin treatment accounted for €2'212. After a time horizon of 22.4 years, average remaining long-term costs accounted for €42'208 or €38'795 in the alitretinoin and the standard treatment arm, respectively. Compared with the standard therapy, the addition of alitretinoin yielded an average gain of 0.230 QALYs at the end of the simulation. Accordingly, the incremental cost-effectiveness ratio resulted in €14'816/QALY gained. These results were robust to changes in key model assumptions.ConclusionThe therapy for CHE patients is currently insufficient. In our long-term model we identified the treatment with alitretinoin as a cost-effective alternative for the therapy of CHE patients in Switzerland.

show abstract

Lebensqualit�t bei Patienten mit berufsbedingten Handekzemen

Cited by 22 publications

References 15 publications

Atopic Dermatitis: Impact on the Quality of Life of Patients and Their Partners

Atopic Dermatitis: Impact on the Quality of Life of Patients and Their Partners

The impact of adverse reactions to injectable filler substances on quality of life: results from the Berlin Injectable Filler Safety (IFS) – study

Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective

Contact Info

Product

Resources

About